Biofrontera

BFRI · NASDAQ

$0.804−$0.0017 (−0.21%)TodayMarket closed · Oct 20, 7:25 PM ET

Prev close $0.8057

BFRI analyst rating

BuyConsensus of 1 analyst over the last 12 months. 100% rate it a buy.

Strong buy0
Buy1
Hold0
Underperform0
Sell0

12-month price target · 4 analysts

Average $6.12 (+661.2% upside)

Low: $3.03
Now: $0.804
High: $9.45

Upgrades and downgrades

The latest rating actions, newest first

BFRI analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Benchmark	May 19, 2026	Downgrade	Buy → Speculative Buy	$3.00	59%

The case for and against

Updated Nov 7, 2025

Bull case

Biofrontera Inc is poised for significant revenue growth due to the anticipated launch of new treatment indications for superficial Basal Cell Carcinoma and Actinic Keratoses in 2026 and 2027. The company's strategy of expanding its sales force, combined with favorable reimbursement policies that enhance Ameluz's market position over traditional cryotherapy, is expected to attract new customers to its photodynamic therapy offerings. Additionally, historical sales trends indicate that the fourth quarter will be crucial for revenue performance, especially with the recent update that allows increased dosing of Ameluz per treatment, potentially leading to higher sales volumes.

Bear case

Biofrontera Inc faces a negative outlook primarily due to its reported revenue of $8.6 million, which fell short of both estimates of $10.6 million and consensus predictions. Furthermore, the potential for regulatory surprises poses significant risks that could adversely affect revenue generation while also increasing operational costs. Lastly, the company's stock price is projected to decrease significantly, with expectations to align closer to a comp group average of 3x 2026 revenue, indicating concerns over its growth and execution capabilities.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.